A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disea… (NCT05092347) | Clinical Trial Compass
RecruitingPhase 1/2
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
United States56 participantsStarted 2022-08-02
Plain-language summary
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation.
Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA.
The study is looking at several other research questions, including:
* Side effects that may be experienced from taking vonsetamig
* How vonsetamig works in the body
* How much vonsetamig is present in the blood
* If vonsetamig works to lower levels of antibodies to HLA
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Has Chronic Kidney Disease (CKD) requiring hemodialysis, and awaiting kidney transplant on the United Network for Organ Sharing (UNOS), with a cPRA ≥99.9%, or those with a cPRA \>98% (98.1% to 99.8%) who have spent 5 years or longer on the waitlist, as defined in the protocol
✓. Adequate hematologic and adequate hepatic function as defined in the protocol
✓. Willing and able to comply with clinic visits and study-related procedures
Exclusion criteria
✕. Current or active malignancy not in remission for at least 1 year
✕. Central nervous system (CNS) pathology or history of CNS neurodegenerative or movement disorders
✕. Patients who have had their spleen removed, including patients with functional asplenia
✕. Patients who have received a stem cell transplantation within 5 years
✕. Use of investigational agents within 8 weeks or 5 half-lives of study drug administration (whichever is larger)
What they're measuring
1
Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period
Timeframe: Up to approximately 6 weeks
2
Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the study
✕. Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone (or anti-inflammatory equivalent) within 72 hours of start of study drug administration
✕. Received a calcineurin inhibitor (eg, tacrolimus, cyclosporine) within 30 days of study drug administration